Loading...

Home
ETF
NAMS

NAMS

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NAMS News

NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost

Jan 16 2026NASDAQ.COM

NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26

Jan 09 2026Newsfilter

NewAmsterdam Grants 40,000 Share Options to Attract New Hires

Dec 05 2025Globenewswire

HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52

Oct 20 2025Benzinga

Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies

Sep 15 2025NASDAQ.COM

NewAmsterdam Pharma Company N.V. (NAMS) Shares Insights at Citi's Biopharma Back to School Conference Transcript

Sep 04 2025Newsfilter

Wells Fargo Begins Coverage of NewAmsterdam Pharma Co with Overweight Rating and Sets Price Target at $45

Aug 25 2025Benzinga

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

Aug 24 2025PRnewswire

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

Aug 22 2025PRnewswire

Piramal Pharma Solutions and NewAmsterdam Pharma Collaborate to Upgrade Oral Solid Dosage Production Facilities at Piramal's Sellersville, Pennsylvania Location

Aug 21 2025Newsfilter

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 21 2025PRnewswire

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

Jul 31 2025Newsfilter

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30 2025Newsfilter

NAMS Makes Bullish Cross Above Critical Moving Average

Jul 09 2025NASDAQ.COM

First Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS)

Jun 23 2025NASDAQ.COM

Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42

Jun 17 2025Benzinga